Physician profile
Robert S Mcfadden
NPI 1356379150
$6,050.62
in general payments reported to CMS, 2019-2025
17 companies · $932 in 2025
The $932 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $631 · 2021: $1,083 · 2022: $704 · 2023: $631 · 2024: $749 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,313.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,281.85 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,189.07 | 2019-2025 | Xifaxan |
| Abbvie INC. | $675.46 | 2019-2024 | |
| Intra-Sana Laboratories | $268.95 | 2021-2022 | |
| Madrigal Pharmaceuticals | $172.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $99.73 | 2024-2025 | |
| Dynavax Technologies Corporation | $59.57 | 2019-2024 | Heplisav-B |
| Eisai INC. | $49.27 | 2023 | |
| Shionogi INC | $45.57 | 2019 | |
| Genzyme Corporation | $39.42 | 2025 | |
| Celltrion USA INC. | $34.85 | 2024-2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $28.74 | 2024 | Iqirvo |
| Astrazeneca Pharmaceuticals LP | $25.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.04 | 2022 | |
| Orphalan INC | $24.02 | 2025 | Cuvrior |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.10 | 2023 | Zerbaxa, Recarbrio, Dificid |
| Caris Mpi, INC. | $14.54 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.